Table 1.
Potential targets of therapy in ovarian cancer.
| Targets | Inhibitors | Studies | NCI study |
|---|---|---|---|
| GOG 218 | |||
| VEGF | Bevacizumab | Phase III [49] | ICON 7 |
| GOG 213 | |||
| OCEANS | |||
|
| |||
| VEGF TKI | Sunitinib | Phase II | NCT00979992 |
| NCT00768144 | |||
| NCT00388037 | |||
| Vatalanib | Phase I (+doce) | NCT00268918 | |
| Sorafenib | Phase II (+carb/pacli) | NCT00390611 | |
| Phase II (+topo) | NCT01047891 | ||
| Phase II | NCT00522301 | ||
| Phase II (+bev) | NCT00436215 | ||
| Phase II [36] | NCT00093626 | ||
| Phase II (+carb/pacli) | NCT00096200 | ||
| Vandetanib | Phae I/II (+bortezomib) | NCT00923247 | |
| Phase II | NCT00445549 | ||
| Phase II(+/− doce) | NCT00872989 | ||
| Cediranib | Phase I/II(+olaparib) | NCT01116648 | |
| Phase II | NCT00275028 | ||
| Phase II (+temsirolimus) | NCT01065662 | ||
| Pazopanib | Phase I/II (+cyclophosphamide) | NCT01238770 | |
| Phase II | NCT01262014 | ||
| Phase I/II [37] | NCT01035658 | ||
| Phase II | NCT00281632 | ||
| Phase III | NCT00866697 | ||
| Vargatef | Phase I (+everolimus) | Pending | |
| AMG 706 | Phase II | NCT00574951 | |
|
| |||
| VEGF TRAP | Aflibercept | Phase II | NCT00327171 |
| Phase II (+doce) | NCT00436501 | ||
|
| |||
| PI3K-PTEN-Akt-mTOR pathway | Temsirolimus | Phase I (+lip Doxo) | NCT00982631 |
| Phase II | NCT00926107 | ||
| Phase II (carb/pacli) | NCT01196429 | ||
| Phase II | NCT00429793 | ||
| Phase I/II(+bev) | NCT01010126 | ||
| Everolimus | Phase II (+bev) | NCT01031381 | |
| Phase II (+/− bev) | NCT00886691 | ||
| Phase II (+lip doxo) | NCT01281514 | ||
| Ridaforolimus | Phase I (+carb/pacli) | NCT01256268 | |
|
| |||
| EGFR | Cetuximab | Phase II (carb/pacli) | NCT00063401/ |
| Phase II (+carb) | NCT00086892 | ||
| Erlotinib | Phase II (+bev) [38] | NCT00130520 | |
| Phase II (+topo) | NCT01003938 | ||
| Phase I/II (+carb/pacli) | NCT00217529 | ||
| Phase II (+carb) | NCT00030446 | ||
| Phase II (+bev after carb/pacli/bev) | NCT00520013 | ||
| Lapatinib | Phase II (+topo) [39] | NCT00436644 | |
| Phase II | NCT00113373 | ||
| Phase I/II (+carb/pacli) | NCT00316407 | ||
|
| |||
| HER2 | Trastuzumab | Phase II [40] | |
| Pertuzumab | Phase II | NCT00058552 | |
| Phase II (+gemcitabine) | NCT00096993 | ||
| Lapatinib | See above | ||
|
| |||
| PARP | ABT 888 | Phase II (+temoz versus lip doxo) | NCT01113957 |
| Phase II (+cyclophosphamide) | NCT01306032 | ||
| Phase I/II (+topo) | NCT01012817 | ||
| Phase I (+carb/pacli/bev) | NCT00989651 | ||
| Olaparib | Phase II (+carb/pacli) | NCT01081951 | |
| Phase I (+carb) | NCT00647062 | ||
| Phase II | NCT00679783 | ||
| Phase II | NCT00494442 | ||
| Phase II (versus lip doxo) | NCT00628251 | ||
| Phase II | NCT00753545 | ||
| Phase II | NCT01033123 | ||
| Iniparib* | Phase II (carb/gemcitabine) | NCT01033292 | |
| Phase II | NCT00677079 | ||
|
| |||
| Epigenetic | Decitabine | Phase II (+carb) | NCT00477386 |
| Phase I (+doxorubicin/vaccine) | NCT00887796 | ||
| Belinostat | Phase I/II (+carb or pacli) | NCT00421889 | |
|
| |||
| MAPK/RAF/MEK pathway | Cabozantinib | Phase I | NCT00940225 |
|
| |||
| HMGA2 | Let-7 microRNA | Preclinical | |
*Iniparib as a true PARP inhibitor is currently under investigation.
Doce: docetaxel, Carb: carboplatin, pacli: paclitaxel, topo: topotecan, bev: bevacizumab, temoz: temozolomide, and lip doxo: liposomal doxorubicin.